REGENERON PHARMACEUTICALS, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
REGENERON PHARMACEUTICALS, INC. (REGN) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of -$300.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-03.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2013-05-03
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2013-03-31 was -$300.00K.
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2011-12-31 was $900.00K.
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2011-09-30 was $600.00K.
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2011-06-30 was $900.00K.
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2011 was $400.00K.
- REGENERON PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2009 was $700.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2013-03-31 | -$300.00K 10-Q · filed 2013-05-03 | |||
| 2011-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $1.50M derived: sum of 2 quarters · filed 2012-02-21 | $2.40M derived: sum of 3 quarters · filed 2012-02-21 | $400.00K 10-K · filed 2012-02-21 |
| 2011-09-30 | $600.00K 10-Q · filed 2011-10-27 | $1.50M derived: sum of 2 quarters · filed 2011-10-27 | -$500.00K 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $900.00K 10-Q · filed 2011-07-28 | $1.10M 10-Q · filed 2011-07-28 | ||
| 2011-03-31 | $200.00K 10-Q · filed 2011-05-03 | |||
| 2009-12-31 | $700.00K 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |